This therapeutic strategy has resulted in a class of drugs called PARP inhibitors (PARPis), which were initially approved as maintenance therapy in patients with recurrent ovarian cancer after response to platinum-based chemotherapy.14, 15, 16 Subsequently, PARPis have also been investigated in ovarian cancer in the first-line setting in several randomized controlled trials (RCTs)17, 18, 19, 20, 21, 22 and have been shown to improve progression-free survival (PFS), especially in patients with germline BRCA1 or BRCA2 mutations. This evidence concerns the gene BRCA1 and ovarian cancer.